bicalutamide

The drug is prescribed for the treatment of advanced prostate cancer in combination with luteinizing hormone-releasing hormone (LHRH) analogues or surgical castration.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Genepharm S.A.

The drug is used for the treatment of advanced prostate cancer in combination with LHRH analogues or surgical castration.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Teva Pharmaceutical Industries Ltd.

The drug is prescribed for the treatment of patients with locally advanced prostate cancer (as monotherapy or as an adjunct to surgery or radiotherapy) in cases of high risk of disease progression. It is also used for the treatment of locally advanced non-metastatic prostate cancer if surgery or castration is impossible or unacceptable.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Teva Pharmaceutical Industries Ltd.

The drug is used for the treatment of advanced prostate cancer in combination with other therapy (LHRH analogues) or surgical castration.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Synthon Hispania S.L.

The drug is prescribed for the treatment of patients with locally advanced prostate cancer at high risk of disease progression. It may be used as monotherapy or as an adjuvant therapy following surgical removal of the gland or radiotherapy. It is also indicated for patients with locally advanced non-metastatic prostate cancer who are not candidates for surgical intervention.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Synthon Hispania S.L.

The drug is used for the treatment of metastatic prostate cancer in combination with surgical castration or with luteinizing hormone-releasing hormone (LHRH) analogues.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Genefarm, S.A.

The drug is prescribed for the treatment of patients with locally advanced prostate cancer (as monotherapy or as an adjunct to surgery or radiotherapy). It is also used in cases where surgery or other medical interventions are unacceptable.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Genefarm, S.A.

The drug is used for the treatment of advanced prostate cancer in combination with surgical castration or with luteinizing hormone-releasing hormone (LHRH) analogues.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Hetero Labs Limited

The drug is prescribed for the treatment of patients with locally advanced prostate cancer (without metastases). It is used as monotherapy or as an adjunct to surgical intervention (radical prostatectomy) or radiotherapy in cases of high risk of disease progression.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Hetero Labs Limited

The drug is used for the treatment of advanced-stage prostate cancer in combination with other therapy (luteinizing hormone-releasing hormone analogues) or surgical castration.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Pharmasciences Inc.

The drug is used for the treatment of advanced prostate cancer in combination with surgical castration or the use of luteinizing hormone-releasing hormone (LHRH) analogues.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Corden Pharma GmbH (manufacturer responsible for manufacturing "in bulk", quality control)

The drug is prescribed for the treatment of patients with locally advanced prostate cancer (without metastases) in cases of high risk of disease progression. It may be used as monotherapy or as an adjunct to surgical intervention or radiotherapy.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Corden Pharma GmbH (responsible for manufacturing "in bulk", quality control)

The drug is used for the treatment of advanced prostate cancer in combination with other hormonal therapy or surgical castration.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Synthon Hispania, S.L.

The drug is intended for the treatment of patients with locally advanced prostate cancer at high risk of disease progression. It can be used as monotherapy or as an adjuvant therapy following surgical intervention or radiotherapy. It is also indicated for patients for whom surgical treatment is not suitable.

Form: tablets, film-coated

ATC: L02BB03

Manufacturer: Synthon Hispania, S.L.